Browse > Article
http://dx.doi.org/10.3345/kjp.2009.52.8.930

Comparison and analysis of the effectiveness to high dose of aspirin and ibuprofen in acute phase of Kawasaki disease  

Keum, Seung-woon (Departments of Pediatrics, Wonkwang University College of Medicine)
Oh, Yeon-kyun (Departments of Pediatrics, Wonkwang University College of Medicine)
Kim, Jong-duck (Departments of Pediatrics, Wonkwang University College of Medicine)
Yu, Seung-taek (Departments of Pediatrics, Wonkwang University College of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.52, no.8, 2009 , pp. 930-937 More about this Journal
Abstract
Purpose : We evaluated the effectiveness of treatment and cardiac complications of replacing a high dose of aspirin with a high dose of ibuprofen for children in acute phase of Kawasaki disease. We also analyzed the possibility of replacing a high dose of aspirin with a high dose of ibuprofen to prevent complications such as Reye󰡑s syndrome caused by aspirin. Methods : One hundred eight children with Kawasaki disease were admitted in the pediatrics department from January 1, 2004 to December 31, 2008. Echocardiography and laboratory tests were performed during diagnosis, and the children were followed-up at 6-8 weeks after the diagnosis. We retrospectively analyzed their characteristics and clinical results. Results : The children were assigned to receive either a high dose of aspirin with intravenous immunoglobulin (IVIG) (aspirin group) or a high dose of ibuprofen with IVIG (ibuprofen group). A total of 55 and 53 children were included in the aspirin and ibuprofen groups, respectively. The mean defervescence period was 6.5${\pm}$2.1 days in the aspirin group, and $6.9{\pm}1.9$ days in the ibuprofen group (P=0.309). The number of failed treatments, during and after treatment, was 8 in the aspirin group and 10 in the ibuprofen group (P=0.547). There were 11 initial cardiac complications in the aspirin group, and 14 in the ibuprofen group, but children who showed improvement at follow-up was 7 and 13 in the aspirin and ibuprofen groups, respectively (P=0.133). Laboratory findings were also improved in both groups. Conclusion : We can be considered whether we will replace high dose of aspirin by high dose of ibuprofen in acute phase of Kawasaki disease. Therefore, we can prevent the severe complications of aspirin use, such as Reye's syndrome.
Keywords
Mucocutaneous Lymph Node Syndrome; Aspirin; Ibuprofen;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16:178-222   PUBMED   ScienceOn
2 Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki disease. N Engl J Med 1991;324:1633-9   DOI   PUBMED   ScienceOn
3 Onouchi Z, Kawasaki T. Overview of pharmacological treatment of Kawasaki disease. Drugs 1999;58:813-22   DOI   ScienceOn
4 Ichida F, Fatica NS, Engle MA, O'Loughlin JE, Klein AA, Snyder MS, et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin. Pediatrics 1987;80:828-35   PUBMED   ScienceOn
5 Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006;18:CD004175
6 Yoshikawa J, Yanagihara K, Owaki T, Kato H, Takagi Y, Okumachi F, et al. Cross-sectional echocardiographic diagnosis of coronary artery aneurysms in patients with the mucocutaneous lymph node syndrome. Circulation 1979;59:133-9   DOI   PUBMED   ScienceOn
7 Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy E, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315: 341-7   DOI   PUBMED   ScienceOn
8 de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998; 133:254-8   DOI   ScienceOn
9 Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9   DOI   PUBMED   ScienceOn
10 Food and Drug Administration U.S. Department of Health and Human Services. Concomitant use of ibuprofen and aspirin. J Pain Palliat Care Pharmacother 2007;21:73-4   PUBMED
11 Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome: report of one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1992;33:67-71   PUBMED
12 Rowley AH, Eckerley CA, Jack HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997;159:5946-55
13 Research Committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Japenase Ministry of Health and Welfare, 1984
14 Leung DY, Meissner HC, Shulman ST, Mason WH, Gerber MA, Glode MP, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr 2002; 140:742-6   DOI   ScienceOn
15 Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y et al. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 2002;105:766-9   DOI   ScienceOn
16 Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed MD, Ferrieri P, et al. Guidelines for long-term management of patients with Kawasaki disease: Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994;89:916-22   PUBMED   ScienceOn
17 Burns JC, Kushner HI, Bastian JF, Shike H, Shimizu C, Matsubara T, et al. Kawasaki disease: A brief history. Pediatrics 2000;106:E27
18 Matsubara T, Mason W, Kashani IA, Kligerman M, Burns JC. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr 1996;128:701-3   DOI   ScienceOn
19 Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93   DOI   ScienceOn
20 Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80   PUBMED   ScienceOn
21 Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cylooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345: 1809-17   DOI   ScienceOn
22 Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001;166:1334-43
23 Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33   DOI   ScienceOn
24 Crystal MA, Manlhiot C, Yeung RS, Smallhorn JF, McCrindle BW. Coronary artery dilation after Kawasaki disease for children within the normal range. Int J Cardiol 2008;1-6   DOI   PUBMED   ScienceOn
25 Nahata MC, Durrell DE, Powell DA, Gupta N. Pharmacokinetics of ibuprofen in febrile children. Eur J Clin Pharmacol 1991;40:427-8   DOI   ScienceOn
26 Kurotobi S, Nagai T, Kawakami N, Sano T. Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatr int 2002;44:1-4   DOI   ScienceOn
27 Burns JC, Mason WH, Glode MP, Shulman ST, Melish ME, Meissner C, et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr 1991;118:680-6   DOI
28 Behan MW, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J 2004;80:155-64   DOI   ScienceOn
29 Rowley AH, Shulman ST. Kawasaki disease. In : Kliegman RM, Jenson HB, Behrman RE, Stanton BF, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia : WB Saunders Co, 2007:1036-42
30 Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004;114:e689-93   DOI   ScienceOn
31 Mulberg AE, Verhave M. Identification and treatment of nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in children. Am J Dis Child 1993;147:1280-1
32 Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001;184:940-3   DOI   ScienceOn
33 Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, Baker SC et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis 2000;182:1183-91   DOI   ScienceOn